Compass Pathways PLC (CMPS) Stock Analysis
Verdict: WATCH (do not buy)
FDA Priority Voucher and positive Phase 3 data de-risk COMP360, but DEA rescheduling and 6-hour clinic delivery impose execution risk.
Investment score: 49/100
Analysis as of
Is Compass Pathways PLC stock worth reviewing? AI model thesis
The model evaluates CMPS as a high-potential but speculative biotech asset. FDA rolling review acceleration and $433.3M in cash secure runway past H1 2027 launch targets, but operational rollout constraints prevent an immediate buy call.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 50/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 45/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Compass Pathways PLC opportunities and risks
What speaks for CMPS
- FDA Rolling Review & Priority Voucher Acceleration
What speaks against CMPS
- FDA Regulatory Approval Failure or Delay Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CMPS | n/a | 0.0x | n/a | 0.0% | 0.0% | -10.5% |
| ROIV | n/a | 3264.0x | n/a | 81.2% | -3534.9% | -3.3% |
| KNSA | 74.9x | 7.4x | 54.3x | 54.5% | 9.6% | 2.9% |
| GNS.L | 5.5x | 2.4x | 12.6x | 93.8% | 43.4% | 5.0% |
| IMCR | n/a | 3.7x | 88.9x | 98.8% | -2.3% | -4.1% |
| OXB.L | n/a | 3.6x | n/a | 36.0% | -23.2% | -5.8% |
| Peer median | n/a | 3.7x | 12.6x | 81.2% | -2.3% | -3.3% |
Frequently asked questions about Compass Pathways PLC (CMPS)
Is CMPS stock a good investment?
The cached TradeMates AI model rates Compass Pathways PLC as WATCH (do not buy) with an investment score of 49/100. The model evaluates CMPS as a high-potential but speculative biotech asset. FDA rolling review acceleration and $433.3M in cash secure runway past H1 2027 launch targets, but operational rollout constraints prevent an immediate buy call. This is algorithmic model output, not personal investment advice.
Is CMPS stock a buy?
The TradeMates model verdict for CMPS is WATCH (do not buy) with an investment score of 49/100. Treat this as a model signal to review, not a personal buy recommendation.